Policosanol
Research reviewed: Up until 03/2026
Policosanol (Long-chain primary aliphatic alcohols (sugar cane / beeswax-derived)) is a dietary supplement with 11 published peer-reviewed studies involving 1,084 participants, researched for LDL Cholesterol & Lipid Profile, Platelet Aggregation & Circulation, Blood Pressure & Cardiovascular Health.
Evidence at a Glance
Strength is scored by study design, sample size, study type, and outcomes
LDL Cholesterol & Lipid Profile
StrongPlatelet Aggregation & Circulation
StrongBlood Pressure & Cardiovascular Health
ModerateResearch Visualised
Visual breakdown of the clinical data.
Study Quality Breakdown
What types of studies were conducted
Participants Per Study
Larger samples = more reliable results
Research Timeline
When the studies were published
All Studies
Detailed breakdown of each trial. Click to expand.
LDL Cholesterol & Lipid Profile
To investigate Cuban policosanol on blood pressure, serum lipoproteins, and cardiometabolic markers in healthy Japanese subjects.
Study Type
Randomised, double-blind, placebo-controlled
Purpose
To investigate Cuban policosanol on blood pressure, serum lipoproteins, and cardiometabolic markers in healthy Japanese subjects.
Dose
10 mg Cuban policosanol daily
Participants
40 healthy Japanese adults
Duration
8 weeks
Results
Policosanol significantly reduced TC (−20%) and TG (−14%) and raised HDL-C 1.3-fold. SBP and DBP were significantly reduced. HbA1c improved.
How They Measured It
Serum lipid panel, blood pressure, HbA1c, HDL function assays
To quantify the effect of policosanol supplementation on blood pressure across RCTs.
Study Type
Systematic review and meta-analysis
Purpose
To quantify the effect of policosanol supplementation on blood pressure across RCTs.
Dose
5–40 mg/day
Participants
Meta-analysis of multiple RCTs
Duration
Various
Results
Policosanol significantly improved both SBP and DBP. Effects were more pronounced in hypertensive subjects. Heterogeneity partly attributable to geographic origin of policosanol source.
How They Measured It
Pooled SBP and DBP changes
To assess policosanol effects on lipid profile and blood pressure in older patients with hypertension and type II hypercholesterolaemia.
Study Type
Randomised, double-blind, placebo-controlled
Purpose
To assess policosanol effects on lipid profile and blood pressure in older patients with hypertension and type II hypercholesterolaemia.
Dose
5–10 mg/day policosanol
Participants
589 older patients with hypertension and hypercholesterolaemia
Duration
12 months
Results
Policosanol significantly reduced LDL-C and TC. Blood pressure modestly but significantly reduced vs placebo. Well tolerated in elderly population.
How They Measured It
Fasting lipid panel, ambulatory blood pressure monitoring
To evaluate Cuban policosanol effects on blood pressure and lipid profile in healthy women.
Study Type
Randomised, double-blind, placebo-controlled
Purpose
To evaluate Cuban policosanol effects on blood pressure and lipid profile in healthy women.
Dose
20 mg Cuban policosanol daily
Participants
40 healthy female volunteers
Duration
8 weeks
Results
Policosanol significantly improved TC, TG, and HDL-C. Blood pressure was meaningfully reduced. HDL efflux capacity improved, suggesting functional cardiovascular benefit beyond lipid lowering.
How They Measured It
Serum lipid panel, blood pressure, HDL functionality
To assess safety and tolerability of policosanol in a geriatric population with elevated cardiovascular risk.
Study Type
Randomised, double-blind, placebo-controlled
Purpose
To assess safety and tolerability of policosanol in a geriatric population with elevated cardiovascular risk.
Dose
10 mg/day policosanol
Participants
215 older adults with cardiovascular risk factors
Duration
24 months
Results
Policosanol was well tolerated with safety profile comparable to placebo. LDL-C improved. No hepatotoxicity or myopathy observed. Supports long-term use in high-risk elderly populations.
How They Measured It
Adverse event monitoring, haematological and biochemical panels
Platelet Aggregation & Circulation
To compare the antiplatelet effects of policosanol vs aspirin in healthy volunteers.
Study Type
Randomised, double-blind, placebo-controlled crossover
Purpose
To compare the antiplatelet effects of policosanol vs aspirin in healthy volunteers.
Dose
10–20 mg/day policosanol vs 100 mg/day aspirin
Participants
43 healthy volunteers
Duration
6 weeks each arm
Results
Policosanol significantly reduced thromboxane B2-induced platelet aggregation, comparable to low-dose aspirin, without prolonging bleeding time. May provide antiplatelet benefit without aspirin's GI side effects.
How They Measured It
Platelet aggregation (collagen- and ADP-induced), bleeding time
To assess whether policosanol's lipid-lowering effects can be independently replicated outside Cuban research.
Study Type
Review — independent evaluation
Purpose
To assess whether policosanol's lipid-lowering effects can be independently replicated outside Cuban research.
Dose
Various (5–40 mg/day)
Participants
Multiple independent trials reviewed
Duration
Various
Results
Independent replication of LDL-C lowering was inconsistent. However, blood pressure and HDL-C improvements were replicated across diverse populations. Geographic origin of policosanol source (Cuban sugar cane vs other) influences outcomes.
How They Measured It
Narrative review of independent non-Cuban RCTs
To assess the impact of Cuban policosanol on HDL function and atherogenic risk in older subjects.
Study Type
Randomised, double-blind, placebo-controlled
Purpose
To assess the impact of Cuban policosanol on HDL function and atherogenic risk in older subjects.
Dose
10–20 mg/day Cuban policosanol
Participants
85 older adults with mild dyslipidaemia
Duration
12 weeks
Results
Policosanol significantly improved HDL efflux capacity and reduced oxidised LDL. TC, LDL-C, and blood pressure improved significantly vs placebo. Results suggest functional cardiovascular protection beyond lipid lowering.
How They Measured It
HDL efflux capacity, oxidised LDL, lipid profile, blood pressure
To evaluate the effects of policosanol on endothelial function and arterial stiffness.
Study Type
Randomised, double-blind, placebo-controlled
Purpose
To evaluate the effects of policosanol on endothelial function and arterial stiffness.
Dose
10 mg/day policosanol
Participants
72 adults with cardiovascular risk factors
Duration
8 weeks
Results
Policosanol significantly improved FMD and reduced arterial stiffness (PWV) vs placebo. Endothelial improvements were accompanied by meaningful blood pressure reductions, suggesting vascular mechanisms beyond lipid modulation.
How They Measured It
Flow-mediated dilation (FMD), pulse wave velocity (PWV), brachial blood pressure
Blood Pressure & Cardiovascular Health
To evaluate policosanol (sugarcane wax alcohols) 20 mg/day in Cuban patients with grade I hypertension.
Study Type
Randomized, Double-Blind, Multicenter
Purpose
To evaluate policosanol (sugarcane wax alcohols) 20 mg/day in Cuban patients with grade I hypertension.
Dose
Policosanol 20 mg/day
Participants
Cuban patients with grade I hypertension
Duration
24 weeks
Results
Policosanol 20 mg/day significantly reduced systolic and diastolic blood pressure and improved lipid profiles in hypertensive patients.
How They Measured It
Systolic and diastolic blood pressure, lipid profile, safety markers
To evaluate policosanol 20 mg/day in Cuban prehypertensive patients.
Study Type
Randomized, Double-Blind, Multicenter
Purpose
To evaluate policosanol 20 mg/day in Cuban prehypertensive patients.
Dose
Policosanol 20 mg/day
Participants
Cuban prehypertensive patients
Duration
24 weeks
Results
Policosanol 20 mg/day effectively reduced blood pressure and improved lipid profiles in prehypertensive patients.
How They Measured It
Blood pressure, lipid profile, inflammatory markers
Frequently Asked Questions
Common questions about Policosanol research
There are currently 11 peer-reviewed studies on Policosanol (Long-chain primary aliphatic alcohols (sugar cane / beeswax-derived)), involving 1,084 total participants. Research covers LDL cholesterol reduction, Blood pressure management, HDL cholesterol improvement and 1 more areas. The overall evidence strength is rated as Strong.
The evidence is currently rated as "Strong Evidence". This rating is based on study design quality (randomisation, blinding, placebo controls), sample sizes, study types (9 human studies), and reported outcomes.
Policosanol has been researched for: LDL cholesterol reduction, Blood pressure management, HDL cholesterol improvement, Platelet aggregation inhibition. Each area has its own body of evidence which you can explore in the study breakdowns above.
Yes, 9 out of 11 studies are human trials. Human trials carry more weight in our evidence scoring system.
Similar Supplements
Other supplements researched for similar health goals
